Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-01

Last Posted Date: 2024-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 236

Registration Number: NCT02253316

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 7 locations

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab IV
Drug: Lenalidomide
Drug: Daratumumab SC
Drug: Dexamethasone

First Posted Date: 2014-09-30

Last Posted Date: 2024-12-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 737

Registration Number: NCT02252172

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma
Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Stage IIIB Mycosis Fungoides/Sezary Syndrome
Stage IVB Mycosis Fungoides/Sezary Syndrome
Anaplastic Large Cell Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage IA Mycosis Fungoides/Sezary Syndrome
Stage IVA Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: romidepsin
Drug: lenalidomide
Other: laboratory biomarker analysis

First Posted Date: 2014-09-05

Last Posted Date: 2024-04-10

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT02232516

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Terminated

Conditions: Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: Lenalidomide
Biological: Obinutuzumab

First Posted Date: 2014-08-26

Last Posted Date: 2022-09-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT02225275

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: lenalidomide
Drug: Subcutaneous bortezomib
Drug: Dexamethasone

First Posted Date: 2014-08-18

Last Posted Date: 2020-07-17

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 42

Registration Number: NCT02219178

Locations: 🇮🇪
Midlands Regional Hospital, Tullamore, Ireland
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇮🇪
Cork University Hospital, Cork, Ireland

and more 5 locations

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-08-13

Last Posted Date: 2024-07-22

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 210

Registration Number: NCT02215980

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1

Active, not recruiting

Conditions: Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: rituximab
Other: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2014-08-12

Last Posted Date: 2023-04-28

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT02213913

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Illinois Cancer Care, Peoria, Illinois, United States

and more 3 locations

Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-08-01

Last Posted Date: 2018-08-02

Lead Sponsor: Fondazione EMN Italy Onlus

Target Recruit Count: 13

Registration Number: NCT02206503

Locations: 🇮🇹
Policlinico Umberto I, Rome, Italy

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Melphalan
Dietary Supplement: Ascorbic acid
Drug: PLD
Drug: Prednisone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2014-08-01

Last Posted Date: 2023-10-31

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 45

Registration Number: NCT02206425

Locations: 🇺🇸
James Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸
cCARE Fresno, Fresno, California, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 9 locations

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Phase 2

Active, not recruiting

Conditions: MULTIPLE MYELOMA (MM)

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-07-30

Last Posted Date: 2024-12-05

Lead Sponsor: Mario Boccadoro

Target Recruit Count: 477

Registration Number: NCT02203643

Locations: 🇮🇹
IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy